\n", " | case.value | \n", "geneSymbol.value | \n", "type.value | \n", "alt_p.value | \n", "
---|---|---|---|---|
0 | \n", "CRC0019 | \n", "KRAS | \n", "point_mutation | \n", "G13D | \n", "
1 | \n", "CRC0021 | \n", "KRAS | \n", "point_mutation | \n", "G12C | \n", "
2 | \n", "CRC0021 | \n", "KRAS | \n", "point_mutation | \n", "G12V | \n", "
3 | \n", "CRC0024 | \n", "KRAS | \n", "point_mutation | \n", "G13C | \n", "
4 | \n", "CRC0027 | \n", "KRAS | \n", "point_mutation | \n", "G13D | \n", "
5 | \n", "CRC0028 | \n", "KRAS | \n", "point_mutation | \n", "G13D | \n", "
6 | \n", "CRC0031 | \n", "KRAS | \n", "point_mutation | \n", "G12D | \n", "
7 | \n", "CRC0053 | \n", "KRAS | \n", "point_mutation | \n", "A146T | \n", "
8 | \n", "CRC0055 | \n", "KRAS | \n", "point_mutation | \n", "G12V | \n", "
9 | \n", "CRC0058 | \n", "KRAS | \n", "point_mutation | \n", "G12V | \n", "
10 | \n", "CRC0060 | \n", "KRAS | \n", "point_mutation | \n", "G12V | \n", "
11 | \n", "CRC0063 | \n", "KRAS | \n", "point_mutation | \n", "G12V | \n", "
12 | \n", "CRC0064 | \n", "KRAS | \n", "point_mutation | \n", "G12D | \n", "
13 | \n", "CRC0067 | \n", "KRAS | \n", "point_mutation | \n", "I36M | \n", "
14 | \n", "CRC0068 | \n", "KRAS | \n", "point_mutation | \n", "G12C | \n", "
15 | \n", "CRC0070 | \n", "KRAS | \n", "point_mutation | \n", "G12D | \n", "
16 | \n", "CRC0073 | \n", "KRAS | \n", "point_mutation | \n", "G12C | \n", "
17 | \n", "CRC0077 | \n", "KRAS | \n", "point_mutation | \n", "G12D | \n", "
18 | \n", "CRC0079 | \n", "BRAF | \n", "point_mutation | \n", "V600E | \n", "
19 | \n", "CRC0080 | \n", "ERBB2 | \n", "feature_amplification | \n", "\n", " |
20 | \n", "CRC0082 | \n", "KRAS | \n", "point_mutation | \n", "G13D | \n", "
21 | \n", "CRC0085 | \n", "KRAS | \n", "point_mutation | \n", "A146T | \n", "
22 | \n", "CRC0094 | \n", "KRAS | \n", "point_mutation | \n", "G12C | \n", "
23 | \n", "CRC0105 | \n", "EGFR | \n", "feature_amplification | \n", "\n", " |
24 | \n", "CRC0106 | \n", "BRAF | \n", "point_mutation | \n", "V600E | \n", "
25 | \n", "CRC0112 | \n", "ERBB2 | \n", "feature_amplification | \n", "\n", " |
26 | \n", "CRC0118 | \n", "BRAF | \n", "point_mutation | \n", "V600E | \n", "
27 | \n", "CRC0124 | \n", "ERBB2 | \n", "point_mutation | \n", "H878Y | \n", "
28 | \n", "CRC0124 | \n", "ERBB2 | \n", "feature_amplification | \n", "\n", " |
29 | \n", "CRC0125 | \n", "KRAS | \n", "point_mutation | \n", "K117N | \n", "
... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "
61 | \n", "CRC0315 | \n", "KRAS | \n", "point_mutation | \n", "G13D | \n", "
62 | \n", "CRC0323 | \n", "BRAF | \n", "point_mutation | \n", "V600E | \n", "
63 | \n", "CRC0324 | \n", "KRAS | \n", "point_mutation | \n", "G12V | \n", "
64 | \n", "CRC0348 | \n", "KRAS | \n", "point_mutation | \n", "G12D | \n", "
65 | \n", "CRC0349 | \n", "KRAS | \n", "point_mutation | \n", "G12D | \n", "
66 | \n", "CRC0382 | \n", "KRAS | \n", "point_mutation | \n", "G12C | \n", "
67 | \n", "CRC0438 | \n", "KRAS | \n", "point_mutation | \n", "Q61K | \n", "
68 | \n", "CRC0468 | \n", "KRAS | \n", "point_mutation | \n", "G12V | \n", "
69 | \n", "CRC0479 | \n", "KRAS | \n", "point_mutation | \n", "G13D | \n", "
70 | \n", "CRC0480 | \n", "BRAF | \n", "point_mutation | \n", "V600E | \n", "
71 | \n", "CRC0481 | \n", "KRAS | \n", "point_mutation | \n", "G13D | \n", "
72 | \n", "CRC0481 | \n", "EGFR | \n", "feature_amplification | \n", "\n", " |
73 | \n", "CRC0484 | \n", "BRAF | \n", "point_mutation | \n", "V600E | \n", "
74 | \n", "CRC0504 | \n", "KRAS | \n", "point_mutation | \n", "G13D | \n", "
75 | \n", "CRC0504 | \n", "ERBB2 | \n", "point_mutation | \n", "R678Q | \n", "
76 | \n", "CRC0508 | \n", "EGFR | \n", "feature_amplification | \n", "\n", " |
77 | \n", "CRC0527 | \n", "BRAF | \n", "point_mutation | \n", "K601N | \n", "
78 | \n", "CRC0527 | \n", "EGFR | \n", "feature_amplification | \n", "\n", " |
79 | \n", "CRC0528 | \n", "BRAF | \n", "point_mutation | \n", "V600E | \n", "
80 | \n", "CRC0610 | \n", "EGFR | \n", "feature_amplification | \n", "\n", " |
81 | \n", "CRC0626 | \n", "KRAS | \n", "point_mutation | \n", "A146V | \n", "
82 | \n", "CRC0714 | \n", "KRAS | \n", "point_mutation | \n", "G13D | \n", "
83 | \n", "CRC0729 | \n", "ERBB2 | \n", "feature_amplification | \n", "\n", " |
84 | \n", "CRC0753 | \n", "KRAS | \n", "point_mutation | \n", "G12V | \n", "
85 | \n", "CRC1063 | \n", "BRAF | \n", "point_mutation | \n", "K601E | \n", "
86 | \n", "CRC1063 | \n", "BRAF | \n", "point_mutation | \n", "T241M | \n", "
87 | \n", "CRC1138 | \n", "BRAF | \n", "point_mutation | \n", "K601E | \n", "
88 | \n", "CRC1169 | \n", "EGFR | \n", "feature_amplification | \n", "\n", " |
89 | \n", "CRC1182 | \n", "KRAS | \n", "point_mutation | \n", "G12A | \n", "
90 | \n", "CRC1278 | \n", "EGFR | \n", "feature_amplification | \n", "\n", " |
91 rows × 4 columns
\n", "\n", " | gene | \n", "cases | \n", "
---|---|---|
0 | \n", "Annotated | \n", "113 | \n", "
1 | \n", "BRAF | \n", "13 | \n", "
2 | \n", "EGFR | \n", "29 | \n", "
3 | \n", "ERBB2 | \n", "11 | \n", "
4 | \n", "KRAS | \n", "70 | \n", "
\n", " | response_type | \n", "cases | \n", "
---|---|---|
0 | \n", "response | \n", "7 | \n", "
1 | \n", "neutral | \n", "26 | \n", "
2 | \n", "progression | \n", "80 | \n", "
\n", " | genes | \n", "DRCl_PD | \n", "DRCl_SD | \n", "DRCl_OR | \n", "tot | \n", "progression | \n", "neutral | \n", "response | \n", "
---|---|---|---|---|---|---|---|---|
0 | \n", "(EGFR,) | \n", "10 | \n", "14 | \n", "5 | \n", "29 | \n", "0.344828 | \n", "0.482759 | \n", "0.172414 | \n", "
1 | \n", "(ERBB2,) | \n", "8 | \n", "1 | \n", "2 | \n", "11 | \n", "0.727273 | \n", "0.0909091 | \n", "0.181818 | \n", "
2 | \n", "(BRAF,) | \n", "13 | \n", "0 | \n", "0 | \n", "13 | \n", "1 | \n", "0 | \n", "0 | \n", "
3 | \n", "(KRAS,) | \n", "56 | \n", "14 | \n", "0 | \n", "70 | \n", "0.8 | \n", "0.2 | \n", "0 | \n", "
4 | \n", "(EGFR, KRAS) | \n", "3 | \n", "3 | \n", "0 | \n", "6 | \n", "0.5 | \n", "0.5 | \n", "0 | \n", "
5 | \n", "(KRAS, ERBB2) | \n", "1 | \n", "0 | \n", "0 | \n", "1 | \n", "1 | \n", "0 | \n", "0 | \n", "
6 | \n", "(BRAF, KRAS) | \n", "2 | \n", "0 | \n", "0 | \n", "2 | \n", "1 | \n", "0 | \n", "0 | \n", "
7 | \n", "(EGFR, BRAF) | \n", "1 | \n", "0 | \n", "0 | \n", "1 | \n", "1 | \n", "0 | \n", "0 | \n", "
8 | \n", "(BRAF, ERBB2) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
9 | \n", "(EGFR, ERBB2) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
10 | \n", "(EGFR, BRAF, KRAS) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
11 | \n", "(BRAF, KRAS, ERBB2) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
12 | \n", "(EGFR, BRAF, ERBB2) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
13 | \n", "(EGFR, KRAS, ERBB2) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
14 | \n", "(EGFR, BRAF, KRAS, ERBB2) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
\n", " | gene | \n", "cases | \n", "
---|---|---|
0 | \n", "Annotated | \n", "25 | \n", "
1 | \n", "BRAF | \n", "0 | \n", "
2 | \n", "EGFR | \n", "19 | \n", "
3 | \n", "ERBB2 | \n", "6 | \n", "
4 | \n", "KRAS | \n", "0 | \n", "
\n", " | response_type | \n", "cases | \n", "
---|---|---|
0 | \n", "response | \n", "7 | \n", "
1 | \n", "neutral | \n", "9 | \n", "
2 | \n", "progression | \n", "9 | \n", "
\n", " | genes | \n", "DRCl_PD | \n", "DRCl_SD | \n", "DRCl_OR | \n", "tot | \n", "progression | \n", "neutral | \n", "response | \n", "
---|---|---|---|---|---|---|---|---|
0 | \n", "(EGFR,) | \n", "5 | \n", "9 | \n", "5 | \n", "19 | \n", "0.263158 | \n", "0.473684 | \n", "0.263158 | \n", "
1 | \n", "(ERBB2,) | \n", "4 | \n", "0 | \n", "2 | \n", "6 | \n", "0.666667 | \n", "0 | \n", "0.333333 | \n", "
2 | \n", "(BRAF,) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
3 | \n", "(KRAS,) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
4 | \n", "(EGFR, KRAS) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
5 | \n", "(KRAS, ERBB2) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
6 | \n", "(BRAF, KRAS) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
7 | \n", "(EGFR, BRAF) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
8 | \n", "(BRAF, ERBB2) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
9 | \n", "(EGFR, ERBB2) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
10 | \n", "(EGFR, BRAF, KRAS) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
11 | \n", "(BRAF, KRAS, ERBB2) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
12 | \n", "(EGFR, BRAF, ERBB2) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
13 | \n", "(EGFR, KRAS, ERBB2) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
14 | \n", "(EGFR, BRAF, KRAS, ERBB2) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
\n", " | gene | \n", "cases | \n", "
---|---|---|
0 | \n", "Annotated | \n", "80 | \n", "
1 | \n", "BRAF | \n", "12 | \n", "
2 | \n", "EGFR | \n", "3 | \n", "
3 | \n", "ERBB2 | \n", "4 | \n", "
4 | \n", "KRAS | \n", "65 | \n", "
\n", " | response_type | \n", "cases | \n", "
---|---|---|
0 | \n", "response | \n", "0 | \n", "
1 | \n", "neutral | \n", "14 | \n", "
2 | \n", "progression | \n", "66 | \n", "
\n", " | genes | \n", "DRCl_PD | \n", "DRCl_SD | \n", "DRCl_OR | \n", "tot | \n", "progression | \n", "neutral | \n", "response | \n", "
---|---|---|---|---|---|---|---|---|
0 | \n", "(EGFR,) | \n", "1 | \n", "2 | \n", "0 | \n", "3 | \n", "0.333333 | \n", "0.666667 | \n", "0 | \n", "
1 | \n", "(ERBB2,) | \n", "3 | \n", "1 | \n", "0 | \n", "4 | \n", "0.75 | \n", "0.25 | \n", "0 | \n", "
2 | \n", "(BRAF,) | \n", "12 | \n", "0 | \n", "0 | \n", "12 | \n", "1 | \n", "0 | \n", "0 | \n", "
3 | \n", "(KRAS,) | \n", "54 | \n", "11 | \n", "0 | \n", "65 | \n", "0.830769 | \n", "0.169231 | \n", "0 | \n", "
4 | \n", "(EGFR, KRAS) | \n", "1 | \n", "0 | \n", "0 | \n", "1 | \n", "1 | \n", "0 | \n", "0 | \n", "
5 | \n", "(KRAS, ERBB2) | \n", "1 | \n", "0 | \n", "0 | \n", "1 | \n", "1 | \n", "0 | \n", "0 | \n", "
6 | \n", "(BRAF, KRAS) | \n", "2 | \n", "0 | \n", "0 | \n", "2 | \n", "1 | \n", "0 | \n", "0 | \n", "
7 | \n", "(EGFR, BRAF) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
8 | \n", "(BRAF, ERBB2) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
9 | \n", "(EGFR, ERBB2) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
10 | \n", "(EGFR, BRAF, KRAS) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
11 | \n", "(BRAF, KRAS, ERBB2) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
12 | \n", "(EGFR, BRAF, ERBB2) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
13 | \n", "(EGFR, KRAS, ERBB2) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
14 | \n", "(EGFR, BRAF, KRAS, ERBB2) | \n", "0 | \n", "0 | \n", "0 | \n", "0 | \n", "\n", " | \n", " | \n", " |
\n", " | geneSymbol.value | \n", "drugLabel.value | \n", "roleLabel.value | \n", "gene_productLabel.value | \n", "
---|---|---|---|---|
0 | \n", "BRAF | \n", "dabrafenib | \n", "enzyme inhibitor | \n", "B-Raf proto-oncogene, serine/threonine kinase | \n", "
1 | \n", "BRAF | \n", "regorafenib | \n", "enzyme inhibitor | \n", "B-Raf proto-oncogene, serine/threonine kinase | \n", "
2 | \n", "BRAF | \n", "sorafenib | \n", "enzyme inhibitor | \n", "B-Raf proto-oncogene, serine/threonine kinase | \n", "
3 | \n", "BRAF | \n", "vemurafenib | \n", "enzyme inhibitor | \n", "B-Raf proto-oncogene, serine/threonine kinase | \n", "
4 | \n", "EGFR | \n", "icotinib | \n", "enzyme inhibitor | \n", "Epidermal growth factor receptor | \n", "
5 | \n", "EGFR | \n", "dacomitinib | \n", "enzyme inhibitor | \n", "Epidermal growth factor receptor | \n", "
6 | \n", "EGFR | \n", "osimertinib | \n", "enzyme inhibitor | \n", "Epidermal growth factor receptor | \n", "
7 | \n", "EGFR | \n", "gefitinib | \n", "enzyme inhibitor | \n", "Epidermal growth factor receptor | \n", "
8 | \n", "EGFR | \n", "erlotinib | \n", "enzyme inhibitor | \n", "Epidermal growth factor receptor | \n", "
9 | \n", "EGFR | \n", "lapatinib | \n", "enzyme inhibitor | \n", "Epidermal growth factor receptor | \n", "
10 | \n", "EGFR | \n", "5-chloro-N2-(4-(4-(dimethylamino)-1-piperidinyl)-2-methoxyphenyl)-N4-(2-(dimethylphosphinyl)phenyl)-2,4-pyrimidinediamine | \n", "enzyme inhibitor | \n", "Epidermal growth factor receptor | \n", "
11 | \n", "EGFR | \n", "afatinib | \n", "enzyme inhibitor | \n", "Epidermal growth factor receptor | \n", "
12 | \n", "EGFR | \n", "canertinib | \n", "enzyme inhibitor | \n", "Epidermal growth factor receptor | \n", "
13 | \n", "EGFR | \n", "neratinib | \n", "enzyme inhibitor | \n", "Epidermal growth factor receptor | \n", "
14 | \n", "EGFR | \n", "vandetanib | \n", "enzyme inhibitor | \n", "Epidermal growth factor receptor | \n", "
15 | \n", "ERBB2 | \n", "dacomitinib | \n", "enzyme inhibitor | \n", "Erb-b2 receptor tyrosine kinase 2 | \n", "
16 | \n", "ERBB2 | \n", "lapatinib | \n", "enzyme inhibitor | \n", "Erb-b2 receptor tyrosine kinase 2 | \n", "
17 | \n", "ERBB2 | \n", "afatinib | \n", "enzyme inhibitor | \n", "Erb-b2 receptor tyrosine kinase 2 | \n", "
18 | \n", "ERBB2 | \n", "canertinib | \n", "enzyme inhibitor | \n", "Erb-b2 receptor tyrosine kinase 2 | \n", "
19 | \n", "ERBB2 | \n", "mubritinib | \n", "enzyme inhibitor | \n", "Erb-b2 receptor tyrosine kinase 2 | \n", "
20 | \n", "ERBB2 | \n", "neratinib | \n", "enzyme inhibitor | \n", "Erb-b2 receptor tyrosine kinase 2 | \n", "
21 | \n", "KRAS | \n", "lonafarnib | \n", "enzyme inhibitor | \n", "KRAS proto-oncogene, GTPase | \n", "
\n", " | chem.type | \n", "chem.value | \n", "
---|---|---|
0 | \n", "literal | \n", "C₂₃H₂₀F₃N₅O₂S₂ | \n", "
\n", " | medical_conditionLabel.value | \n", "referenceLabel.value | \n", "date.value | \n", "
---|---|---|---|
0 | \n", "non-small-cell lung carcinoma | \n", "Drug Indications Extracted from FAERS | \n", "2018-10-02T00:00:00Z | \n", "
1 | \n", "skin cancer | \n", "Drug Indications Extracted from FAERS | \n", "2018-10-02T00:00:00Z | \n", "
2 | \n", "metastatic melanoma | \n", "Drug Indications Extracted from FAERS | \n", "2018-10-02T00:00:00Z | \n", "
3 | \n", "melanoma | \n", "Drug Indications Extracted from FAERS | \n", "2018-10-02T00:00:00Z | \n", "
\n", " | case.value | \n", "variant.value | \n", "geneSymbol.value | \n", "alt_p.value | \n", "annotation_Type.value | \n", "
---|---|---|---|---|---|
0 | \n", "CRC0058 | \n", "Q28371388 | \n", "KRAS | \n", "G12V | \n", "sequence_alteration | \n", "
1 | \n", "CRC0063 | \n", "Q28371388 | \n", "KRAS | \n", "G12V | \n", "sequence_alteration | \n", "
2 | \n", "CRC0309 | \n", "Q28371388 | \n", "KRAS | \n", "G12V | \n", "sequence_alteration | \n", "
3 | \n", "CRC0468 | \n", "Q28371388 | \n", "KRAS | \n", "G12V | \n", "sequence_alteration | \n", "
4 | \n", "CRC0265 | \n", "Q28371388 | \n", "KRAS | \n", "G12V | \n", "sequence_alteration | \n", "
5 | \n", "CRC0261 | \n", "Q28371388 | \n", "KRAS | \n", "G12V | \n", "sequence_alteration | \n", "
6 | \n", "CRC0187 | \n", "Q28371388 | \n", "KRAS | \n", "G12V | \n", "sequence_alteration | \n", "
7 | \n", "CRC0242 | \n", "Q28371388 | \n", "KRAS | \n", "G12V | \n", "sequence_alteration | \n", "
8 | \n", "CRC0324 | \n", "Q28371388 | \n", "KRAS | \n", "G12V | \n", "sequence_alteration | \n", "
9 | \n", "CRC0184 | \n", "Q28371388 | \n", "KRAS | \n", "G12V | \n", "sequence_alteration | \n", "
10 | \n", "CRC0165 | \n", "Q28371388 | \n", "KRAS | \n", "G12V | \n", "sequence_alteration | \n", "
11 | \n", "CRC0021 | \n", "Q28371388 | \n", "KRAS | \n", "G12V | \n", "sequence_alteration | \n", "
12 | \n", "CRC0060 | \n", "Q28371388 | \n", "KRAS | \n", "G12V | \n", "sequence_alteration | \n", "
13 | \n", "CRC0753 | \n", "Q28371388 | \n", "KRAS | \n", "G12V | \n", "sequence_alteration | \n", "
14 | \n", "CRC0055 | \n", "Q28371388 | \n", "KRAS | \n", "G12V | \n", "sequence_alteration | \n", "
15 | \n", "CRC0354 | \n", "Q29938363 | \n", "KRAS | \n", "Q61H | \n", "sequence_alteration | \n", "
16 | \n", "CRC0139 | \n", "Q29938363 | \n", "KRAS | \n", "Q61H | \n", "sequence_alteration | \n", "
17 | \n", "CRC0438 | \n", "Q29938368 | \n", "KRAS | \n", "Q61K | \n", "sequence_alteration | \n", "
18 | \n", "CRC0024 | \n", "Q32948338 | \n", "KRAS | \n", "G13C | \n", "sequence_alteration | \n", "
19 | \n", "CRC0315 | \n", "Q28371015 | \n", "KRAS | \n", "G13D | \n", "sequence_alteration | \n", "
20 | \n", "CRC0127 | \n", "Q28371015 | \n", "KRAS | \n", "G13D | \n", "sequence_alteration | \n", "
21 | \n", "CRC0071 | \n", "Q28371015 | \n", "KRAS | \n", "G13D | \n", "sequence_alteration | \n", "
22 | \n", "CRC0237 | \n", "Q28371015 | \n", "KRAS | \n", "G13D | \n", "sequence_alteration | \n", "
23 | \n", "CRC0018 | \n", "Q28371015 | \n", "KRAS | \n", "G13D | \n", "sequence_alteration | \n", "
24 | \n", "CRC0019 | \n", "Q28371015 | \n", "KRAS | \n", "G13D | \n", "sequence_alteration | \n", "
25 | \n", "CRC0479 | \n", "Q28371015 | \n", "KRAS | \n", "G13D | \n", "sequence_alteration | \n", "
26 | \n", "CRC0504 | \n", "Q28371015 | \n", "KRAS | \n", "G13D | \n", "sequence_alteration | \n", "
27 | \n", "CRC0714 | \n", "Q28371015 | \n", "KRAS | \n", "G13D | \n", "sequence_alteration | \n", "
28 | \n", "CRC0149 | \n", "Q28371015 | \n", "KRAS | \n", "G13D | \n", "sequence_alteration | \n", "
29 | \n", "CRC0082 | \n", "Q28371015 | \n", "KRAS | \n", "G13D | \n", "sequence_alteration | \n", "
... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "
87 | \n", "CRC0362 | \n", "Q28444964 | \n", "EGFR | \n", "\n", " | feature_amplification | \n", "
88 | \n", "CRC0327 | \n", "Q28444964 | \n", "EGFR | \n", "\n", " | feature_amplification | \n", "
89 | \n", "CRC0328 | \n", "Q28444964 | \n", "EGFR | \n", "\n", " | feature_amplification | \n", "
90 | \n", "CRC0449 | \n", "Q28444964 | \n", "EGFR | \n", "\n", " | feature_amplification | \n", "
91 | \n", "CRC0481 | \n", "Q28444964 | \n", "EGFR | \n", "\n", " | feature_amplification | \n", "
92 | \n", "CRC0527 | \n", "Q28444964 | \n", "EGFR | \n", "\n", " | feature_amplification | \n", "
93 | \n", "CRC0537 | \n", "Q28444964 | \n", "EGFR | \n", "\n", " | feature_amplification | \n", "
94 | \n", "CRC0542 | \n", "Q28444964 | \n", "EGFR | \n", "\n", " | feature_amplification | \n", "
95 | \n", "CRC1278 | \n", "Q28444964 | \n", "EGFR | \n", "\n", " | feature_amplification | \n", "
96 | \n", "CRC0480 | \n", "Q21851559 | \n", "BRAF | \n", "V600E | \n", "sequence_alteration | \n", "
97 | \n", "CRC0528 | \n", "Q21851559 | \n", "BRAF | \n", "V600E | \n", "sequence_alteration | \n", "
98 | \n", "CRC0323 | \n", "Q21851559 | \n", "BRAF | \n", "V600E | \n", "sequence_alteration | \n", "
99 | \n", "CRC0118 | \n", "Q21851559 | \n", "BRAF | \n", "V600E | \n", "sequence_alteration | \n", "
100 | \n", "CRC0106 | \n", "Q21851559 | \n", "BRAF | \n", "V600E | \n", "sequence_alteration | \n", "
101 | \n", "CRC0484 | \n", "Q21851559 | \n", "BRAF | \n", "V600E | \n", "sequence_alteration | \n", "
102 | \n", "CRC0079 | \n", "Q21851559 | \n", "BRAF | \n", "V600E | \n", "sequence_alteration | \n", "
103 | \n", "CRC0150 | \n", "Q50092868 | \n", "BRAF | \n", "G466V | \n", "sequence_alteration | \n", "
104 | \n", "CRC1138 | \n", "Q28371540 | \n", "BRAF | \n", "K601E | \n", "sequence_alteration | \n", "
105 | \n", "CRC1063 | \n", "Q28371540 | \n", "BRAF | \n", "K601E | \n", "sequence_alteration | \n", "
106 | \n", "CRC0504 | \n", "Q28370981 | \n", "ERBB2 | \n", "R678Q | \n", "sequence_alteration | \n", "
107 | \n", "CRC0126 | \n", "Q28370984 | \n", "ERBB2 | \n", "V777L | \n", "sequence_alteration | \n", "
108 | \n", "CRC0131 | \n", "Q28370984 | \n", "ERBB2 | \n", "V777L | \n", "sequence_alteration | \n", "
109 | \n", "CRC0124 | \n", "Q29938313 | \n", "ERBB2 | \n", "H878Y | \n", "sequence_alteration | \n", "
110 | \n", "CRC0124 | \n", "Q27908387 | \n", "ERBB2 | \n", "\n", " | feature_amplification | \n", "
111 | \n", "CRC0080 | \n", "Q27908387 | \n", "ERBB2 | \n", "\n", " | feature_amplification | \n", "
112 | \n", "CRC0185 | \n", "Q27908387 | \n", "ERBB2 | \n", "\n", " | feature_amplification | \n", "
113 | \n", "CRC0186 | \n", "Q27908387 | \n", "ERBB2 | \n", "\n", " | feature_amplification | \n", "
114 | \n", "CRC0112 | \n", "Q27908387 | \n", "ERBB2 | \n", "\n", " | feature_amplification | \n", "
115 | \n", "CRC0729 | \n", "Q27908387 | \n", "ERBB2 | \n", "\n", " | feature_amplification | \n", "
116 | \n", "CRC0743 | \n", "Q27908387 | \n", "ERBB2 | \n", "\n", " | feature_amplification | \n", "
117 rows × 5 columns
\n", "\n", " | geneSymbol.value | \n", "variantLabel.value | \n", "treatmentLabel.value | \n", "diseaseLabel.value | \n", "referenceLabel.value | \n", "
---|---|---|---|---|---|
0 | \n", "BRAF | \n", "BRAF G466V | \n", "vemurafenib | \n", "cancer | \n", "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. | \n", "
1 | \n", "BRAF | \n", "BRAF K601E | \n", "vemurafenib | \n", "skin melanoma | \n", "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors | \n", "
2 | \n", "BRAF | \n", "BRAF K601E | \n", "trametinib | \n", "skin melanoma | \n", "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors | \n", "
3 | \n", "BRAF | \n", "BRAF V600E | \n", "cobimetinib fumarate | \n", "cancer | \n", "Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers | \n", "
4 | \n", "BRAF | \n", "BRAF V600E | \n", "irinotecan / Panitumumab / vemurafenib combination therapy | \n", "cholangiocarcinoma | \n", "Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan | \n", "
5 | \n", "BRAF | \n", "BRAF V600E | \n", "vemurafenib | \n", "ovarian cancer | \n", "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. | \n", "
6 | \n", "BRAF | \n", "BRAF V600E | \n", "Dabrafenib / Trametinib combination therapy | \n", "melanoma | \n", "Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations | \n", "
7 | \n", "BRAF | \n", "BRAF V600E | \n", "vemurafenib | \n", "melanoma | \n", "Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study | \n", "
8 | \n", "BRAF | \n", "BRAF V600E | \n", "Dabrafenib / Trametinib combination therapy | \n", "melanoma | \n", "Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. | \n", "
9 | \n", "BRAF | \n", "BRAF V600E | \n", "vemurafenib / cobimetinib fumarate combination therapy | \n", "melanoma | \n", "Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. | \n", "
10 | \n", "BRAF | \n", "BRAF V600E | \n", "pictilisib | \n", "melanoma | \n", "First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. | \n", "
11 | \n", "BRAF | \n", "BRAF V600E | \n", "selumetinib / dactolisib combination therapy | \n", "melanoma | \n", "Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade | \n", "
12 | \n", "BRAF | \n", "BRAF V600E | \n", "vemurafenib | \n", "melanoma | \n", "Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | \n", "
13 | \n", "BRAF | \n", "BRAF V600E | \n", "Dabrafenib / Trametinib combination therapy | \n", "melanoma | \n", "Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. | \n", "
14 | \n", "BRAF | \n", "BRAF V600E | \n", "Dabrafenib / Trametinib combination therapy | \n", "melanoma | \n", "Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. | \n", "
15 | \n", "BRAF | \n", "BRAF V600E | \n", "trametinib / vemurafenib / dabrafenib combination therapy | \n", "gastrointestinal neuroendocrine tumor | \n", "BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy. | \n", "
16 | \n", "BRAF | \n", "BRAF V600E | \n", "Panitumumab / Trametinib combination therapy | \n", "colorectal adenocarcinoma | \n", "Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. | \n", "
17 | \n", "BRAF | \n", "BRAF V600E | \n", "vemurafenib | \n", "laryngeal squamous cell carcinoma | \n", "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. | \n", "
18 | \n", "BRAF | \n", "BRAF V600E | \n", "vemurafenib | \n", "skin melanoma | \n", "Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib | \n", "
19 | \n", "BRAF | \n", "BRAF V600E | \n", "vemurafenib | \n", "skin melanoma | \n", "Improved survival with vemurafenib in melanoma with BRAF V600E mutation | \n", "
20 | \n", "BRAF | \n", "BRAF V600E | \n", "Dabrafenib / Trametinib combination therapy | \n", "skin melanoma | \n", "Improved overall survival in melanoma with combined dabrafenib and trametinib. | \n", "
21 | \n", "BRAF | \n", "BRAF V600E | \n", "Sorafenib / Panitumumab combination therapy | \n", "colorectal cancer | \n", "Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. | \n", "
22 | \n", "BRAF | \n", "BRAF V600E | \n", "Capecitabine / Vemurafenib / Bevacizumab combination therapy | \n", "colorectal cancer | \n", "Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. | \n", "
23 | \n", "BRAF | \n", "BRAF V600E | \n", "vemurafenib | \n", "colorectal cancer | \n", "Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. | \n", "
24 | \n", "BRAF | \n", "BRAF V600E | \n", "Vemurafenib / Gefitinib / Cetuximab combination therapy | \n", "colorectal cancer | \n", "Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. | \n", "
25 | \n", "BRAF | \n", "BRAF V600E | \n", "dabrafenib | \n", "colorectal cancer | \n", "Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. | \n", "
26 | \n", "BRAF | \n", "BRAF V600E | \n", "dactolisib / GDC-0879 combination therapy | \n", "colorectal cancer | \n", "Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. | \n", "
27 | \n", "BRAF | \n", "BRAF V600E | \n", "PLX4720 / GDC0941combination therapy | \n", "colorectal cancer | \n", "A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. | \n", "
28 | \n", "BRAF | \n", "BRAF V600E | \n", "Vemurafenib / Panitumumab combination therapy | \n", "colorectal cancer | \n", "Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. | \n", "
29 | \n", "BRAF | \n", "BRAF V600E | \n", "vemurafenib | \n", "colorectal cancer | \n", "Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. | \n", "
... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "
84 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "ado-trastuzumab emtansine | \n", "Her2-receptor positive breast cancer | \n", "Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. | \n", "
85 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "trastuzumab | \n", "scrotum Paget's disease | \n", "Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature. | \n", "
86 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "trastuzumab | \n", "gastric adenocarcinoma | \n", "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. | \n", "
87 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "lapatinib | \n", "gastric adenocarcinoma | \n", "Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. | \n", "
88 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "Pertuzumab / Trastuzumab combination therapy | \n", "bladder carcinoma | \n", "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. | \n", "
89 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "afatinib | \n", "pancreatic adenocarcinoma | \n", "Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status. | \n", "
90 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "Pertuzumab / Trastuzumab combination therapy | \n", "biliary tract cancer | \n", "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. | \n", "
91 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "Trastuzumab / Lapatinib combination therapy | \n", "colorectal cancer | \n", "Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. | \n", "
92 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "Pertuzumab / Trastuzumab combination therapy | \n", "colorectal cancer | \n", "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. | \n", "
93 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "Trastuzumab / irinotecan combination therapy | \n", "lung small cell carcinoma | \n", "Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer. | \n", "
94 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "trastuzumab | \n", "uterine corpus serous adenocarcinoma | \n", "Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. | \n", "
95 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "Pertuzumab / Trastuzumab combination therapy | \n", "pancreatic cancer | \n", "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. | \n", "
96 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "trastuzumab | \n", "non-small-cell lung carcinoma | \n", "Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. | \n", "
97 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "trastuzumab | \n", "non-small-cell lung carcinoma | \n", "Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. | \n", "
98 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "ado-trastuzumab emtansine | \n", "non-small-cell lung carcinoma | \n", "Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. | \n", "
99 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "dacomitinib | \n", "non-small-cell lung carcinoma | \n", "Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors | \n", "
100 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "trastuzumab | \n", "endometrial cancer | \n", "Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. | \n", "
101 | \n", "KRAS | \n", "KRAS A146T | \n", "selumetinib / dactolisib combination therapy | \n", "colorectal cancer | \n", "Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. | \n", "
102 | \n", "KRAS | \n", "KRAS A146V | \n", "selumetinib / dactolisib combination therapy | \n", "colorectal cancer | \n", "Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. | \n", "
103 | \n", "KRAS | \n", "KRAS A146V | \n", "abemaciclib | \n", "non-small-cell lung carcinoma | \n", "Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. | \n", "
104 | \n", "KRAS | \n", "KRAS G12C | \n", "selumetinib / dactolisib combination therapy | \n", "colorectal cancer | \n", "Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. | \n", "
105 | \n", "KRAS | \n", "KRAS G12C | \n", "selumetinib / docetaxel trihydrate combination therapy | \n", "non-small-cell lung carcinoma | \n", "Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer | \n", "
106 | \n", "KRAS | \n", "KRAS G12D | \n", "MK-2206 | \n", "pancreatic carcinoma | \n", "First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. | \n", "
107 | \n", "KRAS | \n", "KRAS G12D | \n", "selumetinib / dactolisib combination therapy | \n", "colorectal cancer | \n", "Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. | \n", "
108 | \n", "KRAS | \n", "KRAS G12D | \n", "selumetinib / dactolisib combination therapy | \n", "non-small-cell lung carcinoma | \n", "Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. | \n", "
109 | \n", "KRAS | \n", "KRAS G12V | \n", "selumetinib / dactolisib combination therapy | \n", "colorectal cancer | \n", "Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. | \n", "
110 | \n", "KRAS | \n", "KRAS G12V | \n", "palbociclib | \n", "non-small-cell lung carcinoma | \n", "A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. | \n", "
111 | \n", "KRAS | \n", "KRAS G12V | \n", "selumetinib / docetaxel trihydrate combination therapy | \n", "non-small-cell lung carcinoma | \n", "Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer | \n", "
112 | \n", "KRAS | \n", "KRAS G13D | \n", "Cetuximab | \n", "colorectal cancer | \n", "Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. | \n", "
113 | \n", "KRAS | \n", "KRAS G13D | \n", "selumetinib / dactolisib combination therapy | \n", "colorectal cancer | \n", "Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. | \n", "
114 rows × 5 columns
\n", "\n", " | geneSymbol.value | \n", "variantLabel.value | \n", "treatmentLabel.value | \n", "diseaseLabel.value | \n", "referenceLabel.value | \n", "
---|---|---|---|---|---|
0 | \n", "BRAF | \n", "BRAF V600E | \n", "vemurafenib | \n", "melanoma | \n", "Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. | \n", "
1 | \n", "BRAF | \n", "BRAF V600E | \n", "pd-0325901 | \n", "melanoma | \n", "Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. | \n", "
2 | \n", "BRAF | \n", "BRAF V600E | \n", "trametinib | \n", "melanoma | \n", "Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. | \n", "
3 | \n", "BRAF | \n", "BRAF V600E | \n", "Panitumumab | \n", "colorectal cancer | \n", "Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer | \n", "
4 | \n", "BRAF | \n", "BRAF V600E | \n", "Cetuximab | \n", "colorectal cancer | \n", "Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer | \n", "
5 | \n", "BRAF | \n", "BRAF V600E | \n", "Panitumumab | \n", "colorectal cancer | \n", "Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. | \n", "
6 | \n", "BRAF | \n", "BRAF V600E | \n", "Cetuximab | \n", "colorectal cancer | \n", "Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. | \n", "
7 | \n", "BRAF | \n", "BRAF V600E | \n", "Cetuximab | \n", "colorectal cancer | \n", "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. | \n", "
8 | \n", "BRAF | \n", "BRAF V600E | \n", "Oxaliplatin | \n", "colorectal cancer | \n", "Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. | \n", "
9 | \n", "BRAF | \n", "BRAF V600E | \n", "irinotecan | \n", "colorectal cancer | \n", "Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. | \n", "
10 | \n", "BRAF | \n", "BRAF V600E | \n", "dabrafenib | \n", "non-small-cell lung carcinoma | \n", "Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. | \n", "
11 | \n", "EGFR | \n", "EGFR G465R | \n", "Panitumumab | \n", "colorectal cancer | \n", "The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer. | \n", "
12 | \n", "EGFR | \n", "EGFR G465R | \n", "Cetuximab | \n", "colorectal cancer | \n", "The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer. | \n", "
13 | \n", "EGFR | \n", "EGFR AMPLIFICATION | \n", "osimertinib | \n", "non-small-cell lung carcinoma | \n", "Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. | \n", "
14 | \n", "EGFR | \n", "EGFR AMPLIFICATION | \n", "rociletinib | \n", "non-small-cell lung carcinoma | \n", "Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. | \n", "
15 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "Cetuximab | \n", "colorectal cancer | \n", "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. | \n", "
16 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "Panitumumab | \n", "colorectal cancer | \n", "HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. | \n", "
17 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "Cetuximab | \n", "colorectal cancer | \n", "HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. | \n", "
18 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "Cetuximab / capecitabine / Oxaliplatin combination therapy | \n", "colorectal cancer | \n", "HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. | \n", "
19 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "Cetuximab | \n", "colorectal cancer | \n", "HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF. | \n", "
20 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "gefitinib | \n", "adenocarcinoma of the lung | \n", "Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. | \n", "
21 | \n", "ERBB2 | \n", "ERBB2 AMPLIFICATION | \n", "erlotinib | \n", "adenocarcinoma of the lung | \n", "Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. | \n", "
22 | \n", "KRAS | \n", "KRAS A146T | \n", "Cetuximab | \n", "colorectal cancer | \n", "Genomic and biological characterization of exon 4 KRAS mutations in human cancer | \n", "
23 | \n", "KRAS | \n", "KRAS A146T | \n", "FOLFOX-4 / Cetuximab combination therapy | \n", "colorectal cancer | \n", "FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study. | \n", "
24 | \n", "KRAS | \n", "KRAS G12A | \n", "Panitumumab | \n", "colorectal cancer | \n", "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. | \n", "
25 | \n", "KRAS | \n", "KRAS G12A | \n", "Cetuximab | \n", "colorectal cancer | \n", "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. | \n", "
26 | \n", "KRAS | \n", "KRAS G12A | \n", "regorafenib | \n", "colorectal cancer | \n", "KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer. | \n", "
27 | \n", "KRAS | \n", "KRAS G12A | \n", "melphalan | \n", "multiple myeloma | \n", "Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation. | \n", "
28 | \n", "KRAS | \n", "KRAS G12A | \n", "melphalan | \n", "multiple myeloma | \n", "Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance. | \n", "
29 | \n", "KRAS | \n", "KRAS G12A | \n", "melphalan | \n", "multiple myeloma | \n", "Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response. | \n", "
... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "
33 | \n", "KRAS | \n", "KRAS G12A | \n", "erlotinib | \n", "adenocarcinoma of the lung | \n", "Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones | \n", "
34 | \n", "KRAS | \n", "KRAS G12C | \n", "gefitinib | \n", "colorectal cancer | \n", "The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. | \n", "
35 | \n", "KRAS | \n", "KRAS G12C | \n", "erlotinib | \n", "colorectal cancer | \n", "The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. | \n", "
36 | \n", "KRAS | \n", "KRAS G12C | \n", "melphalan | \n", "multiple myeloma | \n", "Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance. | \n", "
37 | \n", "KRAS | \n", "KRAS G12C | \n", "melphalan | \n", "multiple myeloma | \n", "Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan. | \n", "
38 | \n", "KRAS | \n", "KRAS G12C | \n", "gefitinib | \n", "lung cancer | \n", "PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. | \n", "
39 | \n", "KRAS | \n", "KRAS G12D | \n", "vemurafenib | \n", "melanoma | \n", "Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy | \n", "
40 | \n", "KRAS | \n", "KRAS G12D | \n", "Panitumumab | \n", "colorectal cancer | \n", "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. | \n", "
41 | \n", "KRAS | \n", "KRAS G12D | \n", "Cetuximab | \n", "colorectal cancer | \n", "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. | \n", "
42 | \n", "KRAS | \n", "KRAS G12D | \n", "vemurafenib | \n", "hairy cell leukemia | \n", "Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia | \n", "
43 | \n", "KRAS | \n", "KRAS G12D | \n", "melphalan | \n", "multiple myeloma | \n", "Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance. | \n", "
44 | \n", "KRAS | \n", "KRAS G12D | \n", "melphalan | \n", "multiple myeloma | \n", "Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan. | \n", "
45 | \n", "KRAS | \n", "KRAS G12D | \n", "gefitinib | \n", "lung cancer | \n", "PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. | \n", "
46 | \n", "KRAS | \n", "KRAS G12R | \n", "Cetuximab | \n", "colorectal cancer | \n", "Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer | \n", "
47 | \n", "KRAS | \n", "KRAS G12S | \n", "Panitumumab | \n", "colorectal cancer | \n", "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. | \n", "
48 | \n", "KRAS | \n", "KRAS G12S | \n", "Cetuximab | \n", "colorectal cancer | \n", "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. | \n", "
49 | \n", "KRAS | \n", "KRAS G12S | \n", "melphalan | \n", "multiple myeloma | \n", "Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance. | \n", "
50 | \n", "KRAS | \n", "KRAS G12S | \n", "melphalan | \n", "multiple myeloma | \n", "Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response. | \n", "
51 | \n", "KRAS | \n", "KRAS G12S | \n", "melphalan | \n", "multiple myeloma | \n", "Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan. | \n", "
52 | \n", "KRAS | \n", "KRAS G12S | \n", "gefitinib | \n", "lung cancer | \n", "PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. | \n", "
53 | \n", "KRAS | \n", "KRAS G12V | \n", "crizotinib | \n", "cancer | \n", "Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary. | \n", "
54 | \n", "KRAS | \n", "KRAS G12V | \n", "Panitumumab | \n", "colorectal cancer | \n", "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. | \n", "
55 | \n", "KRAS | \n", "KRAS G12V | \n", "Cetuximab | \n", "colorectal cancer | \n", "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. | \n", "
56 | \n", "KRAS | \n", "KRAS G12V | \n", "Cetuximab | \n", "colorectal cancer | \n", "Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. | \n", "
57 | \n", "KRAS | \n", "KRAS G12V | \n", "gefitinib | \n", "lung cancer | \n", "PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. | \n", "
58 | \n", "KRAS | \n", "KRAS G13D | \n", "Panitumumab | \n", "colorectal cancer | \n", "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. | \n", "
59 | \n", "KRAS | \n", "KRAS G13D | \n", "Cetuximab | \n", "colorectal cancer | \n", "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. | \n", "
60 | \n", "KRAS | \n", "KRAS G13D | \n", "Cetuximab | \n", "colorectal cancer | \n", "Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. | \n", "
61 | \n", "KRAS | \n", "KRAS G13D | \n", "Cetuximab | \n", "colorectal cancer | \n", "Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival. | \n", "
62 | \n", "KRAS | \n", "KRAS G13D | \n", "Cetuximab | \n", "colorectal cancer | \n", "Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours. | \n", "
63 rows × 5 columns
\n", "\n", " | geneSymbol.value | \n", "variantLabel.value | \n", "treatmentLabel.value | \n", "diseaseLabel.value | \n", "referenceLabel.value | \n", "
---|---|---|---|---|---|
0 | \n", "EGFR | \n", "EGFR AMPLIFICATION | \n", "Cetuximab / platinum / fluorouracil combination therapy | \n", "head and neck squamous cell carcinoma | \n", "Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. | \n", "
1 | \n", "EGFR | \n", "EGFR AMPLIFICATION | \n", "Cetuximab | \n", "colorectal cancer | \n", "Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. | \n", "
2 | \n", "EGFR | \n", "EGFR AMPLIFICATION | \n", "Panitumumab | \n", "colorectal cancer | \n", "EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis. | \n", "
3 | \n", "EGFR | \n", "EGFR AMPLIFICATION | \n", "Cetuximab | \n", "colorectal cancer | \n", "EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis. | \n", "
4 | \n", "EGFR | \n", "EGFR AMPLIFICATION | \n", "EGFR inhibitor | \n", "non-small-cell lung carcinoma | \n", "EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer. | \n", "
5 | \n", "EGFR | \n", "EGFR AMPLIFICATION | \n", "gefitinib | \n", "non-small-cell lung carcinoma | \n", "Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC. | \n", "
6 | \n", "EGFR | \n", "EGFR AMPLIFICATION | \n", "erlotinib | \n", "non-small-cell lung carcinoma | \n", "Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC. | \n", "
7 | \n", "KRAS | \n", "KRAS G13D | \n", "Cetuximab | \n", "colorectal cancer | \n", "Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. | \n", "
8 | \n", "KRAS | \n", "KRAS G13D | \n", "selumetinib / dactolisib combination therapy | \n", "colorectal cancer | \n", "Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. | \n", "
\n", " | geneSymbol.value | \n", "variantLabel.value | \n", "treatmentLabel.value | \n", "diseaseLabel.value | \n", "referenceLabel.value | \n", "
---|---|---|---|---|---|
0 | \n", "EGFR | \n", "EGFR AMPLIFICATION | \n", "osimertinib | \n", "non-small-cell lung carcinoma | \n", "Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. | \n", "
1 | \n", "EGFR | \n", "EGFR AMPLIFICATION | \n", "rociletinib | \n", "non-small-cell lung carcinoma | \n", "Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. | \n", "
2 | \n", "KRAS | \n", "KRAS G13D | \n", "Panitumumab | \n", "colorectal cancer | \n", "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. | \n", "
3 | \n", "KRAS | \n", "KRAS G13D | \n", "Cetuximab | \n", "colorectal cancer | \n", "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. | \n", "
4 | \n", "KRAS | \n", "KRAS G13D | \n", "Cetuximab | \n", "colorectal cancer | \n", "Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. | \n", "
5 | \n", "KRAS | \n", "KRAS G13D | \n", "Cetuximab | \n", "colorectal cancer | \n", "Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival. | \n", "
6 | \n", "KRAS | \n", "KRAS G13D | \n", "Cetuximab | \n", "colorectal cancer | \n", "Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours. | \n", "
\n", " | type.value | \n", "cases.value | \n", "
---|---|---|
0 | \n", "http://las.ircc.it/ontology/annotationplatform#DRCl_PD | \n", "38 | \n", "
1 | \n", "http://las.ircc.it/ontology/annotationplatform#DRCl_SD | \n", "58 | \n", "
2 | \n", "http://las.ircc.it/ontology/annotationplatform#DRCl_OR | \n", "29 | \n", "